Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
| ▸ | CDK9 | P50750 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 4/20 | 0.54 |
| ▸ | IGF1R | P08069 | 4/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916362 | 0.84 | CDK7 (0.60) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL29400320 | 0.84 | CDK7 (0.60) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL19313060 | 0.83 | CDK7 (0.59) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL26717249 | 0.83 | INSR (0.72) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL29833319 | 0.82 | CDK7 (0.61) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL13832208 | 0.82 | CDK7 (0.61) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL14240702 | 0.82 | CDK7 (0.58) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL19669895 | 0.81 | CDK7 (0.66) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL24817756 | 0.78 | CDK7 (0.62) | CDK7CDK9INSRIGF1RALK | |
| SCHEMBL23534113 | 0.77 | ALK (0.57) | CDK7CDK9INSRIGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2021125803-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | CDK7 588/4885CDK9 241/4885INSR 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.